DexTech Medical AB (XSAT:DEX) Dividends Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSAT:DEX DexTech Medical AB XSAT:DEX
19 GF Score
Price kr10.35
! 3 Warning Signs
View Full Analysis

What is DexTech Medical AB Dividends Received?

Dividends Received only applicable to companies reporting Cash Flow from Operations in direct method.

XSAT:DEX
19GF Score
DexTech Medical AB XSAT:DEX
Dividends Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

DexTech Medical AB Business Description

Address Dag Hammarskjolds Vag 34A, Uppsala, SWE, 752 37
DexTech Medical AB is a Swedish research company specializing in drug development for urological oncology, with a prominent focus on prostate cancer. The company develops drug candidates using a proprietary carbohydrate platform, advancing treatments aimed at castration-resistant prostate cancer and related conditions. Its operations center on research, development, and licensing of these drug candidates. It has four drug candidates: OsteoDex, SomaDex, PSMA-binding conjugates, and GuaDex.
19GF Score

Get the complete analysis for XSAT:DEX

Dividends Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr10.35
Price